{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06352723",
            "orgStudyIdInfo": {
                "id": "2024P000856"
            },
            "organization": {
                "fullName": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Cenobamate in the Intensive Care Unit",
            "officialTitle": "Use of Cenobamate in the Intensive Care Unit for Acute Frequent Seizures and Status Epilepticus",
            "acronym": "CENOBITE",
            "therapeuticArea": [
                "Other",
                "Neurology"
            ],
            "study": "cenobamate-in-the-intensive-care-unit"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-03",
            "studyFirstSubmitQcDate": "2024-04-03",
            "studyFirstPostDateStruct": {
                "date": "2024-04-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jong Woo Lee",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Brigham and Women's Hospital"
            },
            "leadSponsor": {
                "name": "Brigham and Women's Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its own approval from their institutional review board. Data will be shared through the MGB REDCap; raw EEG files will be shared through the MGB Dropbox and analyzed at the BWH.\n\nMonitoring for the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a potential adverse reaction, will be a key aspect of the study. Regular assessments, including RegiSCAR scoring (a validated scoring system for DREeSS5), daily serum cenobamate level measurements, and comprehensive lab tests, will be conducted to ensure patient safety and the effective management of any adverse reactions such as DRESS syndrome."
        },
        "conditionsModule": {
            "conditions": [
                "Epilepsy",
                "Neurologic Disorder"
            ],
            "keywords": [
                "ICU"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Single arm pilot study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cenobamate",
                    "type": "EXPERIMENTAL",
                    "description": "400mg load plus 100mg a day for maximum of 14 days",
                    "interventionNames": [
                        "Drug: Cenobamate"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cenobamate",
                    "description": "Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)\n\n* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.\n* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7",
                    "armGroupLabels": [
                        "Cenobamate"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Target level",
                    "description": "Percentage of patients reaching target level of 10\u00b12 ug/mL after load.",
                    "timeFrame": "6 hours after bolus"
                },
                {
                    "measure": "Maintenance level",
                    "description": "Percentage of patients maintaining daily therapeutic level of 10\u00b12 ug/mL",
                    "timeFrame": "Up to 14 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Seizure cessation",
                    "description": "Percentage of seizure cessation within 24 hours of reaching the target level.",
                    "timeFrame": "Up to 14 days"
                },
                {
                    "measure": "Seizure burden change",
                    "description": "Percentage change in seizure burden over 24 hours",
                    "timeFrame": "Up to 14 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-70.\n* Undergoing EEG monitoring.\n* Acute frequent seizures (\\>1/hour) or status epilepticus (\\>5 min of consecutive seizures, or seizure burden \\>20% within past 1 hour).\n* Adjunctive conventional antiseizure medication indicated.\n\nExclusion Criteria:\n\n* History of medication-related rash.\n* On medication or device affecting enteral absorption (e.g., phenobarbital, pentobarbital).\n* Counterindication to cenobamate as described in the prescribing information.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jong Woo Lee, MD, PhD",
                    "role": "CONTACT",
                    "phone": "617-732-7547",
                    "email": "jlee38@bwh.harvard.edu"
                },
                {
                    "name": "Melanie Choe, BA",
                    "role": "CONTACT",
                    "phone": "617-525-3014",
                    "email": "mlchoe@bwh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jong Woo Lee, MD, PhD",
                    "affiliation": "Brigham and Women's Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Brigham and Women's Hospital",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "37064924",
                    "type": "BACKGROUND",
                    "citation": "Carlson JM, Molyneaux BJ, Lee JW. Safe Use of Cenobamate in Super Refractory Status Epilepticus: A Case Series. Neurohospitalist. 2023 Apr;13(2):169-172. doi: 10.1177/19418744221147083. Epub 2023 Feb 15."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7983",
                    "name": "Epilepsy",
                    "relevance": "LOW"
                },
                {
                    "id": "M16018",
                    "name": "Status Epilepticus",
                    "relevance": "LOW"
                },
                {
                    "id": "M15452",
                    "name": "Seizures",
                    "relevance": "LOW"
                },
                {
                    "id": "T5471",
                    "name": "Status Epilepticus",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000654784",
                    "term": "Cenobamate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M272774",
                    "name": "Cenobamate",
                    "asFound": "ECLS",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}